Navigation Links
FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
Date:2/10/2009

NERVIANO, Italy, February 10 /PRNewswire/ --

- Nerviano Medical Sciences (NMS): Green Light From the FDA for the CDC7 Inhibitor

Nerviano Medical Sciences (NMS) has secured Food and Drug Administration (FDA) approval to conduct for the first time clinical trials of a novel antitumoral agent. The drug blocks Cdc7, a protein that is responsible for the uncontrolled proliferation of cancer cells. The preclinical data, recently published on the prestigious journal Nature Chemical Biology ( http://www.nature.com/nchembio/journal/v4/n6/full/nchembio.90.html), demonstrate that inhibition of Cdc7 induces tumor cell death and blocks the growth of various types of cancer in experimental animal models.

The FDA approval will allow to conduct clinical phase I trials in cancer patients. "The news that the FDA has approved the clinical experimentation of our Cdc7 inhibitor - explains Dr. Francesco Colotta, NMS Oncology VP - first of all represents an acknowledgment of the quality and innovation of Italian research in the field of oncology. The discovery of this new drug results exclusively from the efforts of our investigators at the NMS R&D Site in Nerviano; thanks to their competence and passion we will be the first in the world to explore this new antitumor mechanism".

About Nerviano Medical Sciences (NMS)

Nerviano Medical Sciences is the largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe. Research activities in Nerviano generate on average two clinical candidate molecules per year. NMS takes advantage of strategic alliances with biotechnology as well as pharmaceutical companies to secure its long term business sustainability. The Company has already finalized partnerships with major companies such as Pfizer Inc., Bristol-Myers Squibb Co., Genentech Inc. as well as with several biotech companies and academic institutions.

For information:

Nerviano Medical Sciences

Maria D'Acquino, tel +39(0)331-581013, mob. +39(0)335-1863051, maria.dacquino@nervianoms.com


'/>"/>
SOURCE Nerviano Medical Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves KAPIDEX(TM) (Dexlansoprazole) delayed release capsules for the Treatment of GERD
2. Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project
3. Monsanto Board Approves 10 Percent Dividend Increase
4. FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B & Hepatitis C
5. MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) --
6. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
7. AUDIO from Medialink and GlaxoSmithKline: FDA Approves Boostrix for Adults
8. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
9. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
10. FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
11. FDA Approves Durameds LoSEASONIQUE(R) Oral Contraceptive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... CAMBRIDGE, Mass. and ... 4, 2016 SystemOne, a company focused ... platforms for the developing world, and Daktari Diagnostics, ... reality with its portable and ultrasensitive immunoassay-based CarePlatform™, ... development and license agreement to integrate Daktari,s technology ...
(Date:12/2/2016)... Dec. 2, 2016 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced the appointment of ... industry consultant, and private healthcare investor, to its Board ... leader with clinical and strategic experience at the highest ... and CEO. "As one of the world,s leading orthopedic ...
(Date:12/2/2016)... NC (PRWEB) , ... December 01, 2016 , ... ... US Computational Science Symposium (CSS) and the popularity of US Single Day Events ... take place in early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical ...
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the Prudential Center ... 3rd, 2016. The event, which is held on the United Nations International Day of ... Disabilities back into the workplace. Suitable Technologies is partnering with NTI to showcase how ...
Breaking Biology Technology:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
(Date:11/17/2016)... it has just released a new white paper authored by Zettar that covers the ... transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated endeavor ...
Breaking Biology News(10 mins):